KRAS G12D-IN-37

KRAS G12D-IN-37 是一种 KRASG12D 抑制剂,对 KRASG12D 突变肿瘤细胞具有抗增殖活性且对正常细胞毒性极低,它通过与 His 95、Arg 68 和 Asp 12 残基形成氢键相互作用而稳定结合 KRASG12D 并抑制下游 ERK/AKT 信号通路,同时可提升活性氧 (ROS) 水平、诱导细胞凋亡 (apoptosis)、破坏线粒体膜电位、下调抗凋亡蛋白 Bcl-2 并上调促凋亡蛋白 Bax 和 caspase 3,可用于胃腺癌和结直肠癌等癌症相关研究。
KRAS G12D-IN-37
产品编号: MS-S57013 分子式: C29H34F3N5O3 分子量: 557.61
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

KRAS G12D-IN-37 是一种 KRASG12D 抑制剂,对 KRASG12D 突变肿瘤细胞具有抗增殖活性且对正常细胞毒性极低,它通过与 His 95、Arg 68 和 Asp 12 残基形成氢键相互作用而稳定结合 KRASG12D 并抑制下游 ERK/AKT 信号通路,同时可提升活性氧 (ROS) 水平、诱导细胞凋亡 (apoptosis)、破坏线粒体膜电位、下调抗凋亡蛋白 Bcl-2 并上调促凋亡蛋白 Bax 和 caspase 3,可用于胃腺癌和结直肠癌等癌症相关研究。

生物实验数据

生物活性 KRAS G12D-IN-37 is a KRASG12D inhibitor that exhibits antiproliferative activity against KRASG12D-mutant tumor cells with minimal cytotoxicity to normal cells, stably binds KRASG12D through hydrogen-bonding interactions with His 95, Arg 68, and Asp 12 residues to inhibit downstream ERK/AKT signaling, elevates reactive oxygen species (ROS) levels, induces apoptosis, disrupts mitochondrial membrane potential, downregulates the anti-apoptotic protein Bcl-2 while upregulating the pro-apoptotic proteins Bax and caspase 3, and can be used for cancer-related research such as gastric adenocarcinoma and colorectal cancer.
IC50 & Target

KRas G12D

 

Bcl-2

 

Bax

 

Caspase 3

 

体外研究
(In Vitro)

KRAS G12D-IN-37 (Compound 16k) (72 h) 可强效抑制 KRASG12D 突变型 AGS 和 GP2D 细胞的增殖,其 IC50 值分别为 0.18 μM 和 0.21 μM,而对其他 KRAS 突变型细胞、KRAS 野生型细胞以及正常 HIEC 细胞的活性较低。
KRAS G12D-IN-37 (0.31-2.5 μM; 24-72 h) 对 KRASG12D 突变型 AGS 和 GP2D 细胞表现出时间依赖性细胞毒性。
KRAS G12D-IN-37 (0.0625-0.5 μM; 14 days) 可剂量依赖性地强效抑制 KRASG12D 突变型 AGS 和 GP2D 细胞的集落形成。
KRAS G12D-IN-37 (0.625-2.5 μM; 6 h) 可在 KRASG12D 突变型 AGS 和 GP2D 细胞中抑制 KRAS 下游的 ERK/AKT 信号通路,并以剂量依赖方式降低 p-ERK 和 p-AKT 的水平。
KRAS G12D-IN-37 (0.625-2.5 μM; 24 h) 可剂量依赖性地增强 KRASG12D 突变型 AGS 和 GP2D 细胞内的 ROS 积累,并破坏线粒体膜电位。
KRAS G12D-IN-37 (0.625-5 μM; 24 h) 可剂量依赖性地诱导 KRASG12D 突变型 AGS 和 GP2D 细胞发生凋亡,呈剂量依赖性地改变促凋亡与抗凋亡蛋白的平衡,并提高 Caspase 3 活性。
KRAS G12D-IN-37 (1 μM) 在大鼠肝微粒体中表现出良好的代谢稳定性,半衰期为 289 min。

Cell Proliferation Assay

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.0625, 0.125, 0.25, 0.5 μM
Incubation Time: 14 days (medium changes every 72 h)
Result: Dose-dependently inhibited colony formation of AGS and GP2D cells.
Almost entirely suppressed AGS cell colony formation at 0.25 μM; almost entirely suppressed GP2D cell colony formation at 0.5 μM.
Showed superior colony formation inhibition efficacy compared to MRTX 1133 (MS-M67046).

Western Blot Analysis

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 6 h
Result: Decreased the phosphorylation of ERK and AKT in AGS and GP2D cells.
Reduced p-AKT levels by 90% and p-ERK levels by 70% in GP2D cells at 2.5 μM; the effect on p-AKT/AKT was comparable to that of MRTX 1133.
Caused p-ERK levels to rebound at 1.25 μM in GP2D cells, potentially due to negative feedback in RAS signaling.

Apoptosis Analysis

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 24 h
Result: Induced apoptosis in AGS and GP2D cells in a dose-dependent manner.
Induced apoptosis in 80% of AGS cells at 5 μM; induced apoptosis in a high proportion of GP2D cells at 2.5 μM.
Induced higher apoptosis rates than MRTX 1133, with most apoptotic events occurring in the early stage.

Western Blot Analysis

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 24 h
Result: Dose-dependently upregulated the levels of pro-apoptotic proteins Bax and Caspase 3, and downregulated the level of anti-apoptotic protein Bcl-2 in AGS and GP2D cells.
Dose-dependently increased Caspase 3 activity in both cell lines.
体内研究
(In Vivo)

KRAS G12D-IN-37 (Compound 16k) (500-1500 mg/kg;口服;单次给药) 在昆明小鼠中表现出良好的体内安全性特征,其 LD50 约为 1270 mg/kg。

Animal Model: Healthy Kunming mice (equally divided by sex)
Dosage: 1500 mg/kg; 1200 mg/kg; 1000 mg/kg; 500 mg/kg
Administration: p.o.; single dose
Result: Caused death of all mice at 1500 mg/kg.
Led to death of 2 of 6 mice at 1200 mg/kg, with a calculated median lethal dose (LD50) of approximately 1270 mg/kg.
Showed no notable weight loss or physical abnormalities in mice treated with 500 mg/kg or 1000 mg/kg over 14 days.
Revealed no significant morphological changes or cellular abnormalities in heart, liver, spleen, lungs, and kidneys of mice treated with 1000 mg/kg.

化学信息

分子量 557.61
分子式 C29H34F3N5O3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础